ProCE Banner Activity

The Evolving Role of VEGF Targeted Agents in Treating Solid Tumors

Text Module

In this interactive module, an expert panel reviews the most recent data informing optimal use of VEGFR-targeted TKIs for treating patients with solid organ tumors.

Released: November 15, 2019

Expiration: November 13, 2020

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Learning Objectives

  • Compare VEGF-targeted TKIs, taking into consideration the available clinical evidence and their current US and global indications for the treatment of solid tumors
  • Develop adverse event management strategies for patients with solid tumors receiving VEGF-targeted TKIs
  • Identify suitable patients with solid tumors for first-line treatment with VEGF-targeted TKIs
  • Select patients with solid tumors for whom a VEGF-targeted TKI is an appropriate second-line choice
  • Sequence VEGF-targeted TKIs with other drug classes to maximize benefit and quality of life for patients with solid tumors

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Armo, AstraZeneca, Imugene, Immuneering, and Pieris.

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Eli Lilly, Merck, Novartis, Pfizer, and Roche/Genentech.

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peleton, and Pfizer and consulting fees from AstraZeneca, Bristol-Myers Squibb, Incyte, Janssen, Merck, and Pfizer.

Staff Disclosure

Staff

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.